Preimplantation Genetic Testing Market (Technology - Single-nucleotide Polymorphism, Next-generation Sequencing, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, and Polymerase Chain Reaction; Procedure Type - Preimplantation Genetic Screening, and Preimplantation Genetic Diagnosis; Application - Single Gene Disorders, HLA Typing, Structural Chromosomal Abnormalities, X-linked Disorders, Aneuploidy, and Gender Identification; End User - Fertility Clinics, Hospitals, Diagnostics Laboratories, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Preimplantation Genetic Testing Market (Technology - Single-nucleotide Polymorphism, Next-generation Sequencing, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, and Polymerase Chain Reaction; Procedure Type - Preimplantation Genetic Screening, and Preimplantation Genetic Diagnosis; Application - Single Gene Disorders, HLA Typing, Structural Chromosomal Abnormalities, X-linked Disorders, Aneuploidy, and Gender Identification; End User - Fertility Clinics, Hospitals, Diagnostics Laboratories, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01443 Category: Healthcare & Medical Devices Published: January, 2024

A recent report published by Infinium Global Research on preimplantation genetic testing market provides in-depth analysis of segments and sub-segments in the global as well as regional preimplantation genetic testing market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional preimplantation genetic testing market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global preimplantation genetic testing market.

Market Insight:

The global preimplantation genetic testing market was valued at USD 769.8 million in 2022 and is expected to reach USD 1,325 million in 2030, with a CAGR of 7.04% during the forecast period 2023-2030.

Preimplantation Genetic Testing (PGT) is a specialized genetic diagnostic procedure conducted during In Vitro Fertilization (IVF) to assess the genetic makeup of embryos before they are implanted into the uterus. This technique is designed to identify genetic abnormalities, chromosomal disorders, or specific gene mutations that may be present in embryos, allowing for the selection of embryos with a lower risk of genetic disorders. The PGT process typically involves the biopsy of one or a few cells from the developing embryo, usually at the blastocyst stage. These cells are then analyzed to detect any genetic anomalies. The technology used in PGT includes various molecular and cytogenetic techniques such as Single-Nucleotide Polymorphism (SNP), Next-Generation Sequencing (NGS), Fluorescence in Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), and Polymerase Chain Reaction (PCR). There are two primary types of PGT procedures: Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD). PGS involves the screening of embryos for chromosomal abnormalities, helping to select embryos with the correct number of chromosomes, thereby reducing the risk of miscarriage and implantation failure. PGD, on the other hand, is used to identify specific genetic disorders or mutations, allowing couples with known genetic conditions to make informed decisions about embryo selection.

The growth of the Preimplantation Genetic Testing (PGT) market is being fueled by the increasing prevalence of genetic disorders. As the incidence of genetic abnormalities rises, there is a growing demand for PGT services to identify and mitigate the risks associated with these conditions. Additionally, the decreasing fertility in females with advancing age is expected to stimulate the growth of the market. As more women opt for delayed childbearing, the heightened risk of chromosomal abnormalities creates a need for PGT as a crucial tool for assessing and ensuring the genetic health of embryos before implantation. However, the high cost associated with preimplantation genetic testing can hamper market growth. Affordability remains a concern for many individuals and couples, and the expense associated with these procedures may limit the widespread adoption of PGT. Nonetheless, improving healthcare infrastructure and the rising medical tourism in emerging countries provide lucrative opportunities for the growth of the market. As these nations enhance their healthcare capabilities, there is an increasing likelihood of more individuals gaining access to advanced reproductive technologies, including PGT, thereby contributing to the market's growth in the forecasted period.

Preimplantation Genetic Testing Market Size, Share IGR

The global preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, and the rest of the world. The North America region is expected to hold the maximum share of the market during the forecasted period. The region's advanced healthcare infrastructure and well-established Assisted Reproductive Technology (ART) practices. North America is home to numerous fertility clinics, diagnostic laboratories, and healthcare facilities equipped with state-of-the-art technologies, making PGT services more readily available and accessible. Additionally, factors such as a higher prevalence of delayed childbearing and a greater acceptance of ART procedures in North America contribute to the increased demand for preimplantation genetic testing. The region's economic prosperity and relatively higher healthcare spending also enable individuals and couples to afford these advanced reproductive technologies. Moreover, the Asia Pacific region is anticipated to grab a significant share of the market during the forecasted period. The Asia Pacific region has been witnessing rapid advancements in healthcare infrastructure and technologies. The growing prevalence of infertility issues and rising awareness of available reproductive solutions have led to an increased demand for PGT services. Fertility clinics and diagnostic laboratories in countries across the Asia Pacific are progressively incorporating advanced genetic testing technologies, such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), to offer comprehensive PGT solutions which are expected to drive the growth of the market in the region in the forecasted period.

Report Scope of the Preimplantation Genetic Testing Market:

Report Coverage Details
Market Size in 2022 USD 769.8 Million
Market Size by 2030 USD 1,325 Million
Growth Rate from 2023 to 2030 CAGR of 7.04%
Largest Market North America
No. of Pages 300
Market Drivers
  • The rising prevalence of genetic disorders is driving the growth of the market.

  • Decreasing female fertility with age is expected to stimulate the growth of the market.

Market Segmentation By Technology, By Procedure Type, By Application, and By End User
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global preimplantation genetic testing market covers segments such as technology, procedure type, application, and end user. On the basis of technology, the sub-markets include single-nucleotide polymorphism, next-generation sequencing, fluorescence in situ hybridization, comparative genomic hybridization, and polymerase chain reaction. On the basis of procedure type, the sub-markets include preimplantation genetic screening, and preimplantation genetic diagnosis. On the basis of application, the sub-markets include single gene disorders, HLA typing, structural chromosomal abnormalities, X-linked disorders, aneuploidy, and gender identification. On the basis of end user, the sub-markets include fertility clinics, hospitals, diagnostics laboratories, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Revvity, Thermo Fisher Scientific Inc, Abbott, Agilent Technologies, Inc., Oxford Gene Technology IP Limited, Quest Diagnostics Incorporated, Natera, Inc., A CooperSurgical Fertility Company, Genea Pty Limited, and Illumina, Inc..

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the preimplantation genetic testing market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global preimplantation genetic testing market was valued at USD 769.8 Million in 2022.
It is likely to grow at a CAGR of 7.04% during the forecast period 2023-2030.
The global preimplantation genetic testing market is estimated to reach USD 1,325 Million by the end of 2030.
North America is anticipated to exhibit high demand for preimplantation genetic testing market during the forecast period.
Revvity, Thermo Fisher Scientific Inc, Abbott, Agilent Technologies, Inc., Oxford Gene Technology IP Limited, Quest Diagnostics Incorporated, Natera, Inc., A CooperSurgical Fertility Company, Genea Pty Limited, and Illumina, Inc..

Request Quote


10% off on our research study. Get it through instant purchase.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.